RIMOUSKI, Québec, Dec. 23, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to announce the execution of definitive agreements with NB Gold Inc. (“NB Gold”), a private company, and Comet Lithium Corporation (TSXV: CLIC) (“Comet”) on December 23, 2024 to acquire the McKenzie Gold Project as described previously on November 18, 2024. On the heels of its Williams Brook Project (“Williams Brook”) Option agreement with Kinross Gold (see Oct. 24, 2024 News Release), Puma aimed to secure and gain control over a second large and highly prospective mining exploration project. The Mackenzie Gold Project, located only 7 km west of Williams Brook, shares many of its characteristics and hosts many high-grade gold occurrences (up to 1,315 g/t Au) on the extensive property package....

CANTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) — Destination XL Group, Inc, (NASDAQ: DXLG), the leading integrated – commerce specialty retailer of Big + Tall men’s clothing and shoes, today confirmed that it has received a non-binding proposal from Fund 1 Investments, LLC to acquire all of the outstanding shares of the Company. The Board of Directors regularly reviews opportunities to create and enhance shareholder value and will carefully review and evaluate this proposal and other strategic alternatives together with its financial and legal advisors. Guggenheim Securities, LLC is acting as financial advisor and Greenberg Traurig, LLP is acting as legal advisor to the Company. About Destination XL Group, Inc. Destination XL Group, Inc. is the leading retailer of Men’s Big + Tall apparel that provides the Big + Tall man...

MONTREAL, Dec. 23, 2024 (GLOBE NEWSWIRE) — Stingray (TSX: RAY.A; RAY.B), an industry leader in music and video content distribution, business services, and advertising solutions, today announced the acquisition of Loupe Art, a leading visual art streaming service on Smart TVs and Digital Signage. This strategic acquisition aims to expand Stingray’s presence on Connected TVs and significantly enhance its offering for businesses, particularly in digital signage. Founded in 2016, Loupe Art’s platform includes over 10,000 original artworks from more than 750 artists across 50 countries. It offers expertly curated art collections and themed episodes that combine visual art with music, providing an unparalleled ambient entertainment experience. Loupe Art reaches audiences worldwide through partnerships with major platforms...

 BOLLORÉ PRESS RELEASE December 23, 2024 INCREASE IN THE PRICE AND EXCHANGE RATIO OF PUBLIC BUYOUT OFFERS FOLLOWED BY MANDATORY SQUEEZE-OUTS ON THE SHARES OF COMPAGNIE DU CAMBODGE, FINANCIÈRE MONCEY AND SOCIÉTÉ INDUSTRIELLE ET FINANCIÈRE DE L’ARTOIS Bolloré SE decided today to raise the price and the exchange ratio in Universal Music Group (UMG) shares of the public buyout offers followed by mandatory squeeze-outs announced on September 12, 2024, for Compagnie du Cambodge, Financière Moncey and Société Industrielle et Financière de l’Artois shares as follows:for Bolloré SE’s tender offer on Compagnie du Cambodge:Cash offer: EUR 110 per Compagnie du Cambodge share, representing an increase of 18.28% compared to the initial price of EUR 93; Exchange offer: 4.69 UMG shares for 1 Compagnie du Cambodge share, compared to the initial exchange...

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular’s common stock prior to the September 12, 2024 public disclosure of Deerfield’s initial acquisition proposal. The Singular Genomics Board of Directors formed a special committee composed entirely of independent and disinterested directors (the “Special Committee”) to evaluate...

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed The transaction is expected to close in mid-2025 BOSTON and SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”) announced they...

CHAMPAIGN, Ill. and LEAWOOD, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) — First Busey Corporation (“First Busey”) (Nasdaq: BUSE), the holding company of Busey Bank, and CrossFirst Bankshares, Inc. (“CrossFirst”) (Nasdaq: CFB), the holding company of CrossFirst Bank, today jointly announced that First Busey shareholders and CrossFirst shareholders have each voted to adopt and approve, as applicable, all proposals relating to the previously announced merger in which First Busey will acquire CrossFirst. The special shareholder meetings were held on Friday, December 20, 2024. “Our shareholders’ overwhelming approval of this business combination is an important milestone in the process of closing this transaction,” said First Busey Chairman and CEO Van Dukeman. “This approval reflects our shareholders’ confidence in this compelling merger...

CHAMPAIGN, Ill. and LEAWOOD, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) — First Busey Corporation (“First Busey”) (Nasdaq: BUSE), the holding company of Busey Bank, and CrossFirst Bankshares, Inc. (“CrossFirst”) (Nasdaq: CFB), the holding company of CrossFirst Bank, today jointly announced that First Busey shareholders and CrossFirst shareholders have each voted to adopt and approve, as applicable, all proposals relating to the previously announced merger in which First Busey will acquire CrossFirst. The special shareholder meetings were held on Friday, December 20, 2024. “Our shareholders’ overwhelming approval of this business combination is an important milestone in the process of closing this transaction,” said First Busey Chairman and CEO Van Dukeman. “This approval reflects our shareholders’ confidence in this compelling merger...

TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) — PIMCO Canada Corp. (“PIMCO Canada”) is pleased to announce that the previously announced reorganization of PIMCO Tactical Income Fund (TSX: PTI.UN), PIMCO Tactical Income Opportunities Fund (TSX: PTO.UN) and PIMCO Multi-Sector Income Fund (TSX: PIX.UN) (collectively, the “Funds”) with PIMCO Monthly Enhanced Income Fund (“PMEI”) (the “Mergers”) was completed following the close of business on December 20, 2024.  Pursuant to the Mergers, PMEI acquired all of the outstanding units of each Fund in exchange for Class A units (the “PMEI Units”) of PMEI.  Each unitholder of each Fund received, as of the close of business on December 20, 2024, such number of PMEI Units as is equal to the number of units of the applicable Fund held multiplied by the exchange ratio noted in the table below (the “Exchange...

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed The transaction is expected to close in mid-2025 BOSTON, Mass. and SAN DIEGO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”)...